NCT06659120招募中不适用
Fremanezumab for the Prevention of Menstrually-related Migraine Attacks - a Prospective, Observational Study According to Routine Neurological Care in Switzerland
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Change of migraine days per month
研究概览
简要总结
The goal of this observational study is to compare, in real-world clinical practice, the effect of fremanezumab on menstrual migraine to the effect of fremanezumab on non-perimenstrual attacks. The main question it aims to answer is, if menstrually-related migraine attacks respond equally well to anti-CGRP mAb treatment with fremanezumab as non-menstrually-related attacks.
Participants diagnosed with episodic or chronic migraine with menstrually-related migraine with or without aura and treated with fremanzumab according to the SmPC will be required to maintain a headache diary over at least 3 months prior to and 6 months after fremanezumab initiation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Premenopausal women of 18 years of age or older.
- •Women with a regular cycle 21-32 days.
- •The patient has a diagnosis of chronic or episodic migraine.
- •Women suffering from migraine with or without aura according to International Headache Society (IHS) Classification (ICHD-3 code A1.1.2 or A1.2.0.2) for at least one year.
- •Women suffering of at least 2 days of menstrually-related migraine per period on average in the last three periods (baseline measurements and inclusion criteria).
- •The patient has been maintaining a daily headache diary as part of her routine disease management per her treating physician and has 3 months headache diary data prior to baseline/ treatment initiation. Notes: The patient's headache diary captures information on each headache day, headache duration, headache severity, medication intake, each day of menstrual bleeding, pain intensity of symptoms associated with the menstrual bleeding and symptoms of endometriosis (if present): dysmenorrhoea, dyschezia, dyspareunia, dysuria.
- •The patient understands and is willing to keep records in their headache diary for the course of the study.
- •Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
- •The patient has signed the informed consent.
排除标准
- •Patients with pure menstrual migraine.
- •The patient is treated with another anti-CGRP mAb.
- •The patient is not treated with fremanezumab according to the SmPC.
- •The patient is being treated with another anti-CGRP-based preventive migraine medication within 6 months of enrolment.
- •The patient is participating in an interventional clinical trial in EM or CM.
- •Change of hormone therapy during study treatment.
- •Progestin-only contraception.
研究组 & 干预措施
Women with menstrually-related migraine attacks
- Premenopausal women of 18 years of age or older.
- Women with a regular cycle 21-32 days.
- The patient has a diagnosis of chronic or episodic migraine.
- Women suffering from migraine with or without aura according to International Headache Society (IHS) Classification (ICHD-3 code A1.1.2 or A1.2.0.2) for at least one year.
- Women suffering of at least 2 days of menstrually-related migraine per period on average in the last three periods (baseline measurements and inclusion criteria).
干预措施: Fremanezumab (Drug)
结局指标
主要结局
Change of migraine days per month
时间窗: 6 months
Difference in relative reduction of migraine days per month between menstrually-related and non-menstrual migraine days at follow-up (months 4 to 6 after initiation of anti-CGRP mAb) compared to baseline (months -3 to -1 prior to initiation).
次要结局
- Change of disability score MIDAS in points(6 months)
- Change of headache-related disability score HIT-6 in points(6 months)
- Migraine-specific quality of life in MSQ score in points(6 months)
- Anxiety in GAD-7 score, in points(6 months)
- Depression in PHQ-8 score, in points(6 months)
- Change of fatigue assessed by FSS in points(6 months)
- Endometriosis symptoms(6 months)
- Hormonal treatment(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeMigraineNCT04464707Teva Branded Pharmaceutical Products R&D, Inc.292
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineMigraineNCT05458011Teva Branded Pharmaceutical Products R&D, Inc.365
已完成
3 期
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeMigraineNCT04458857Teva Branded Pharmaceutical Products R&D, Inc.235
终止
3 期
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)Chronic Cluster HeadacheNCT02964338Teva Branded Pharmaceutical Products R&D, Inc.259
终止
2 期
A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With FibromyalgiaFibromyalgiaNCT03965091Teva Branded Pharmaceutical Products R&D, Inc.189